Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 11, 2009, Pages 1843-1851

  Gui, T ^a,e   Reheman, A ^b   Ni, H ^b,c   Gross, P L ^d   Yin, F ^e   Monroe, D ^e   Monahan, P E ^e   Stafford, D W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding time; Collagen IV; Factor IX; Gla domain; Mouse knock in; Thrombosis

Indexed keywords

ALANINE; BLOOD CLOTTING FACTOR 9; COLLAGEN TYPE 4; LYSINE; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD VESSEL OCCLUSION; CELL INTERACTION; CONTROLLED STUDY; DISEASE SEVERITY; GENE MUTATION; HEMOPHILIA B; IN VITRO STUDY; IN VIVO STUDY; KNOCK IN MOUSE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; STRAIN DIFFERENCE; SURVIVAL; THROMBOCYTE; THROMBOSIS; WILD TYPE;

ANIMALS; BINDING SITES; COLLAGEN TYPE IV; FACTOR IX; GENE KNOCK-IN TECHNIQUES; GENETIC VARIATION; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; MICE; PROTEIN BINDING; THROMBOSIS;

EID: 70449453157     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03545.x     Document Type: Article

References (47)

1. Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996, 93:11068-73.
2. Cheung WF, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992, 267:20529-31.
3. Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997, 272:16717-20.
4. Toomey JR, Smith KJ, Roberts HR, Stafford DW. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain. Biochemistry 1992, 31:1806-8.
5. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997, 94:5804-9.
6. Gui T, Lin HF, Jin DY, Hoffman M, Straight DL, Roberts HR, Stafford DW. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002, 100:153-8.
7. Begbie ME, Mamdani A, Gataiance S, Eltringham-Smith LJ, Bhakta V, Hortelano G, Sheffield WP. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thromb Haemost 2005, 94:1138-47.
8. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005, 105:2316-23.
9. Lewis J, Yang B, Detloff P, Smithies O. Gene modification via 'plug and socket' gene targeting. J Clin Invest 1996, 97:3-5.
10. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997, 90:3962-6.
11. Jin DY, Zhang TP, Gui T, Stafford DW, Monahan PE. Creation of a mouse expressing defective human factor IX. Blood 2004, 104:1733-9.
12. Cheung WF, Straight DL, Smith KJ, Lin SW, Roberts HR, Stafford DW. The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells. J Biol Chem 1991, 266:8797-800.
13. Griffith MJ, Breitkreutz L, Trapp H, Briet E, Noyes CM, Lundblad RL, Roberts HR. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. J Clin Invest 1985, 75:4-10.
14. Larson PJ, Stanfield-Oakley SA, VanDusen WJ, Kasper CK, Smith KJ, Monroe DM, High KA. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa. J Biol Chem 1996, 271:3869-76.
15. Hoffman M, Monroe DM, Roberts HR. A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol 1992, 98:531-3.
16. Yan SC, Razzano P, Chao YB, Walls JD, Berg DT, McClure DB, Grinnell BW. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (NY) 1990, 8:655-61.
17. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006, 96:553-61.
18. Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res 1979, 15:191-7.
19. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001, 413:74-8.
20. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000, 106:385-92.
21. Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005, 3:875-83.
22. Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004, 279:14338-46.
23. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003, 102:3609-14.
24. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002, 8:1175-81.
25. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 2006, 107:535-41.
26. Ahmad SS, Rawala-Sheikh R, Cheung WF, Jameson BA, Stafford DW, Walsh PN. High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11. Biochemistry 1994, 33:12048-55.
27. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW. Thrombin generation: a comparison of assays using platelet-poor and- rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol 2007, 139:106-12.
28. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006, 107:3902-6.
29. Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, Poncz M, Camire RM, Arruda VR. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005, 3:2730-7.
30. Broze GJ, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001, 85:747-8.
31. Gailani D, Lasky NM, Broze GJ. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997, 8:134-44.
32. Borchgrevink CF, Waaler BA. The secondary bleeding time; a new method for the differentiation of hemorrhagic diseases. Acta Med Scand 1958, 162:361-74.
33. Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003, 85:290-9.
34. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, Batorova A, Lapecorella M, Schved JF, Ingerslev J, Mariani G. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009, 7:774-9.
35. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007, 5(Suppl. 1):157-66.
36. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005, 3:695-702.
37. Yang H, Reheman A, Chen P, Zhu G, Hynes RO, Freedman J, Wagner DD, Ni H. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006, 4:2230-7.
38. Gui T, Reheman A, Funkhouser WK, Bellinger DA, Hagaman JR, Stafford DW, Monahan PE, Ni H. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 2007, 121:225-34.
39. Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006, 108:3045-52.
40. Rosen ED, Raymond S, Zollman A, Noria F, Sandoval-Cooper M, Shulman A, Merz JL, Castellino FJ. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol 2001, 158:1613-22.
41. Rowley G, Saad S, Giannelli F, Green PM. Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage. Genomics 1995, 30:574-82.
42. Melton LG, Li T, Stafford DW, Gabriel DA. Location of the platelet binding site in zymogen coagulation factor IX. Blood Coagul Fibrinolysis 2001, 12:237-43.
43. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004, 2:561-73.
44. Khoshnoodi J, Pedchenko V, Hudson BG. Mammalian collagen IV. Microsc Res Tech 2008, 71:357-70.
45. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, Verbeuren TJ, Denis CV. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 2008, 112:603-9.
46. Rinaldi N, Willhauck M, Weis D, Brado B, Kern P, Lukoschek M, Schwarz-Eywill M, Barth TF. Loss of collagen type IV in rheumatoid synovia and cytokine effect on the collagen type-IV gene expression in fibroblast-like synoviocytes from rheumatoid arthritis. Virchows Arch 2001, 439:675-82.
47. Pollock LE, Lalor P, Revell PA. Type IV collagen and laminin in the synovial intimal layer: an immunohistochemical study. Rheumatol Int 1990, 9:277-80.